Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

121.72 -5.09 (-4.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
From GeneDx
Via Business Wire
GeneDx to Participate in Upcoming Investor Conference
From GeneDx
Via Business Wire
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
From GeneDx
Via Business Wire
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
From GeneDx
Via Business Wire
The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts
 
Via Benzinga
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
The company provides sequencing tools to help diagnose children with rare diseases. 
Via Investor's Business Daily
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Via The Motley Fool
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
From GeneDx
Via Business Wire
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
From GeneDx
Via Business Wire
Expert Ratings For GeneDx Hldgs
 
Via Benzinga
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
 
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue. 
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
From GeneDx
Via Business Wire
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
From GeneDx
Via Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From GeneDx
Via Business Wire
The Markets Are Ignoring Risk, But That Does Not Mean You Should...
It is Fall clean-up time. Sell lagging and sagging companies. 
Via Talk Markets
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
GeneDx to Participate in Fall Investor Conferences
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
From GeneDx
Via Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.